Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled Trial

30 Jun 2020

Abstract excerpt

It is unclear if genetic variants affect smoking cessation treatment response. This study tested whether variants in the cholinergic receptor nicotinic alpha 5 subunit (CHRNA5) predict response to smoking cessation medication by directly comparing the two most effective smoking cessation pharmacotherapies. In this genotype‐stratified randomized, double‐blind, placebo‐controlled clinical trial (May 2015–August...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nicotinic Acetylcholine Receptors Study
Share to Smoking Behavior and Cessation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32602170
DOI: 10.1002/cpt.1971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled TrialPMID 32602170Read ↗

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.Semantic proximity Read ↗

Variants in nicotinic receptors and risk for nicotine dependence.Semantic proximity Read ↗

Studies towards stratified approaches to smoking cessation with a focus on South Asians and effectiveness of vareniclineSemantic proximity Read ↗

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.Semantic proximity Read ↗

Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.Semantic proximity Read ↗

The nicotinic receptor alpha5 coding polymorphism rs16969968 as a major target in disease: Functional dissection and remaining challenges.Semantic proximity Read ↗

Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment.Semantic proximity Read ↗

A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation.Semantic proximity Read ↗

The Role of Pharmacogenetics in Smoking.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.